Total Funding
5
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2159729
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
D. Jeffrey Keyser: Co-Founder , COOPast Role: Marion Merrell Dow, Senior Management Positions- Henrik Sandvad Rasmussen: CMO & CSOPast Role: British Biotechnology PLC, Senior Vice President for Clinical Research and Regulatory Affairs
About the Company
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions.
The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition
that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.
